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Abstract: Transcription factors are proteins able to bind DNA and induce the transcription of specific
genes. Consequently, they play a pivotal role in multiple cellular pathways and are frequently
over-expressed or dysregulated in cancer. Here, we will focus on a specific “signal transducer and
activator of transcription” (STAT3) factor that is involved in several pathologies, including cancer.
For long time, the mechanism by which STAT3 exerts its cellular functions has been summarized
by a three steps process: (1) Protein phosphorylation by specific kinases, (2) dimerization promoted
by phosphorylation, (3) activation of gene expression by the phosphorylated dimer. Consequently,
most of the inhibitors reported in literature aimed at blocking phosphorylation and dimerization.
However, recent observations reopened the debate and the entire functional mechanism has been
revisited stimulating the scientific community to pursue new inhibition strategies. In particular,
the dimerization of the unphosphorylated species has been experimentally demonstrated and specific
roles proposed also for these dimers. Despite difficulties in the expression and purification of the full
length STAT3, structural biology investigations allowed the determination of atomistic structures of
STAT3 dimers and several protein domains. Starting from this information, computational methods
have been used both to improve the understanding of the STAT3 functional mechanism and to design
new inhibitors to be used as anticancer drugs. In this review, we will focus on the contribution of
structural biology to understand the roles of STAT3, to design new inhibitors and to suggest new
strategies of pharmacological intervention.
Keywords: STAT3; cancer; molecular modeling; drug design; structural biology
1. Introduction
Transcription factors (i.e., DNA binding proteins controlling the rate of gene transcription; TFs)
are nodal points in signaling pathways and among the most frequently affected genes in cancer [1,2].
Signal transducer and activator of transcription (STAT) is a family of cytoplasmic TFs (STAT1, STAT2,
STAT3, STAT4, STAT5a, STAT5b, and STAT6) responsible for the transmission to the nucleus of signals
from multiple receptors and non-receptor associated kinases [3,4].
In this review, we will focus on structural biology studies of a specific member of the STAT family,
namely STAT3, and its implications for comprehension of the protein functional mechanism and the
development of novel anticancer therapies. This protein plays a pivotal role in the regulation of several
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genes involved in proliferation, differentiation, apoptosis, angiogenesis and immuno-inflammatory
processes. Additionally, it has been recently demonstrated that STAT3 also localizes into mitochondria
and that it can influence their function [5–7].
Over the years, enhanced and dysregulated STAT3 activity has been observed in a large number
of cancer cell lines [8], indicating this protein as a promising target for the development of anticancer
therapies [9–12]. In fact, STAT3 drives the expression of proliferation and survival genes, like c-myc,
bcl-XL, mcl-1 [3,13,14]. Furthermore, it has important consequences on the tumor microenvironment by
increasing the expression of pro-angiogenic factors [3,15]. Finally, STAT3 activation in tumors induces
immune-suppressive cytokines and promotes immune-evasion [16–18].
A search in the Web of Science database for papers with the word “STAT3” and “inhibitor” in
the title revealed more than 500 articles published in the last twenty years. This data makes explicit
the great effort made by the scientific community to develop pharmacological therapies based on the
modulation of STAT3 functions.
Despite the significant efforts made, the tendency of the STAT3 to aggregate prevented, until now,
the determination of the structure of the entire protein in both monomeric and dimeric form.
However, several recombinant proteins not prone to aggregation have been expressed and their
structure solved by X-ray crystallography (Table 1). These investigations [19–21] confirmed that
STAT3 shares with other members of the STAT family a peculiar 3D-structure characterized by
six main structural motifs (Figure 1): (1) Amino-terminal domain (NTD), (2) coiled-coil domain,
(3) DNA-binding domain, (4) linker domain (LD), (5) Src Homology 2 (SH2) domain and (6)
trans-activation domain (TAD). The domain at the C-terminal of STAT3, TAD, is intrinsically disordered
and highly conserved between STAT proteins. Several experiments indicate that the TAD is not
involved directly in dimerization interface of many STATs proteins. However, when phosphorylated,
a specific tyrosine residue (Tyr705 in the case of STAT3) included in the TAD can reinforce the
protein-protein interaction binding in a specific site located in the other protein partner [22–25].
Figure 1. (a) Cartoon representation of USTAT3β: DNA structure (PDB ID 4ZIA for the N-termini and
4E68 for the remaining structure). Color keys: cyan = amino-terminal domain; green = coiled-coil domain;
red = DNA-binding domain; yellow = linker domain; blue = SH2 domain; violet = transactivation domain;
orange = DNA. Tyrosine 705 residues are shown as spheres. In the lower part of the picture, a scheme of
STATs domain division is reported; (b) Schemes of STAT3α and STAT3β domain division. The dashed
line represents the core fragment of the STATs domain (inspired by a scheme presented by Chen et al. [26]
for STAT1).
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Different splicing results in two main STAT3 isoforms (α and β) that differ for the length of the
TAD (∼50 residues in STAT3α and ∼7 residues in STAT3β). The biological roles of the two isoforms
have been debated since their discovery. However, because the high disorder that marks this protein
region it has been scarcely characterized from the structural point of view. Therefore, in this review we
will only discuss the other structured domains that are common in both isoforms.
Table 1. STAT3 structures available in the protein data bank (PDB).
PDB Code Description Reference
3CWG Unphosphorylated mouse STAT3 core fragment (full length without amino-terminal domain (NTD)) [19]
1BG1 STAT3B/DNA complex (no N-terminal domain) [21]
4E68 Unphosphorylated STAT3B (no N-terminal domain) core protein binding to dsDNA [20]
4ZIA X-ray structure of STAT3 N-terminal domain [27]
2. Functional Mechanism
Cytokine receptors and growth factor receptors are the main drivers of STAT3 activation.
Moreover, it has been shown that also environmental factors such as smoking cigarettes, infections
and stress can lead to STAT3 triggering by toll-like receptors (TLR), adrenergic receptors and nicotinic
receptors [16].
The interaction of the physiological ligands with their receptors starts the so-called “canonical”
STAT3 activation pathway that involves phosphorylation of a specific tyrosine residue (Tyr705) in the
TAD [3,16]. This post-transcriptional modification is mainly catalyzed by a family of receptor-associated
tyrosine kinases, JAK1–JAK3 and Tyk2 [28], but also by non-receptor kinases like c-src and c-abl [3].
Phosphorylation changes the propensity of STAT3 molecules to form homo-dimers [3]. Similar to
the STAT1 dimer-DNA structure [26,29], while the main dimerization interface is formed by the SH2
domains, the two TADs increase the stability of the dimer by the binding of p-Tyr705 in a specific cavity
located in the SH2 domain of the other monomer. A key element for the p-Tyr705 recognition is the
presence of an arginine, strictly conserved in all known SH2 domain (Arg609 in STAT3) residing in the
interior of the SH2 domain [26]. This arginine residue, because of the favorable electrostatic interaction
energy between the negatively charged phosphate and the positive NH3 amino group, stabilizes the
p-Tyr705 binding. Phosphorylated STAT3 is retained in the nucleus, where it binds to DNA in order to
promote and activate transcription of a wide array of genes controlling cell differentiation, proliferation
and survival in various cell types.
Year after year, is becoming clearer that the phosphorylation–dimerization–activation scheme
does not completely recapitulate the complexity of the STAT3 functional mechanisms and a novel more
complicated picture, involving unphosphorylated STAT3 and other post-transcriptional modifications,
is emerging [30]. For example, the presence of unphosphorylated STAT proteins (USTATs) inside the
nucleus, as well as, their ability to dimerize and bind DNA have been shown experimentally [20,31–34].
Concerning their functional roles, the formation of USTAT3 dimers influences the nuclear localization
of the protein, DNA-binding, chromatin-remodeling and the regulation of specific gene expression [27].
The NTD domain is not directly involved in the formation of phosphorylated STAT3 dimers
or in their interaction with DNA, therefore it was not considered central for the STAT3 functions
for a long time. However, recent studies indicated that NTD has an important role at low cytokine
concentration, i.e., when the activated STAT3 concentration is small. In fact, the NTD domains
seem to facilitate the STAT3 binding to weak STAT3-binding sites by forming tetramers composed
of a pair of phosphorylated dimers [27]. Moreover, both experimental [35] and computational
studies [25,36] indicated that the NTD is part of the dimerization surface in USTAT3 dimers and that
it is important for nuclear accumulation [37], DNA binding [31] and gene expression regulation [38].
Collectively, these studies revealed that also this protein region could be suitable for the development
of new drugs, however, few attempts were done [39,40] and a more intense research activity is required
to develop inhibition strategies based on NTD binding.
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3. Post-Transcriptional Modifications and Their Role in the STAT3 Function
Phosphorylation of tyrosine residues located in the SH2 and TAD domains of STAT proteins by
protein tyrosine kinases (PTKs) has been identified as a critical event for modulating their functions [24,41].
However, other post-transcriptional modifications (PTMs) can influence the protein activity.
For example, STAT3 is subject to phosphorylation on serine 727 (that lacks in STAT3β) by
serine protein kinases, as well as, lysine acetylation and methylation by protein acetyltransferase and
methyltransferases [16,42]. Multiple studies reported about the possible roles of Ser727 phosphorylation
in both protein functions and progression of specific cancers [43]. Moreover, Wakahara et al., reported that
Ser727 phosphorylation regulates the duration of the STAT3 transcriptional activity by bolstering the
p-Tyr705 dephosphorylation [44].
Concerning acetylation, recent studies supported the hypothesis that it modulates different
functions and properties of STAT3 [45] such as protein dimerization [46], transcriptional activity [47],
mitochondrial translocation [48], cardiogenesis [49] and methylation of tumor-suppressor gene
promoters [50]. Other studies lead to the identification of additional acetylation sites: K685, K49,
K87, K679, K707, K709 [45].
Regarding methylation, Lee and coworkers recently demonstrated that Enhancer of Zest Homolog
2 (EZH2), a histone-lysine N-methyltransferase, interacts with and methylates STAT3 increasing its
activity [51].
Finally, in 2014 Mariotto and coworkers reported that the S-Glutathionylation of Cys328 and
Cys542, located in the DNA-binding domain and in the linker domain, respectively, severely impair
STAT3 phosphorylation [52].
4. Structural and Biophysical Investigations
As already pointed out, structural studies on STAT3 and other STAT proteins, have been slowed
down by problems with protein expression and purification due to the tendency of STATs to form
aggregates. As consequence, only domains of the STAT proteins have been solved and the structure of
full length STAT3 is not available in the protein data bank (PDB).
The first structure (PDB code 1BG1) of mouse phosphorylated STAT3β core fragment (i.e., lacking
NTD) in complex with DNA (see Figure 1) was solved in 1998 by Becker and coworkers with
a resolution of 2.25 Å [21]. This structure enabled a detailed characterization of the interaction
between DNA and the STAT3-DNA binding domain and the identification of residues essential for
the interaction. Moreover, the binding of p-Tyr705 to SH2 was characterized in detail. In particular,
the structural studies confirmed that p-Tyr705 forms polar interactions with residues Lys591, Arg609,
Ser611, and Ser613. This information has been crucial for drug design given that the majority of STAT3
inhibitors reported in the literature so far has been designed to compete with p-Tyr705 for the binding
in its SH2 cavity.
In 2008 Chen and coworkers solved by X-ray crystallography the structure of the monomeric
core fragment of USTAT3 (PDB code 3CWG) at a resolution of 3.05 Å [19]. This study confirmed that
STAT3 and USTAT3 have essentially an identical structure and indicated that the core fragment is
primarily monomeric.
The same core fragment, with the NTD replaced by green fluorescent protein (GFP), was solved
in complex with DNA (PDB code 3E68) at a resolution of 2.65 Å by Nkansah et al., in 2013 [20].
Notably, in this case, it was possible to observe for the first time the complex formed by two USTAT3
molecules and a DNA fragment, demonstrating that Tyr705 phosphorylation is not the only event
triggering STAT3 dependent transcription.
Finally, in 2015 the first structure of the NTD was published by Frank and coworkers [27].
During their experiment, the authors found that the removal of the first two residues (Met1 and Ala2)
from the protein sequence significantly increased the protein solubility. In particular, they expressed
different constructs (residues 3 to 120, 3 to 124, 3 to 126, 3 to 130, 3 to 135, and 3 to 138), but only the one
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with residues from 2 to 138 produced crystals. The obtained 3D structure of STAT3-NTD monomers is
very similar to those of STAT1 [53] and STAT4 [54].
Concerning the interaction between multiple NTD, the asymmetric unit of the crystal is formed
by five NTDs and two different protein-protein interaction surfaces were observed, one indicated
as ‘“handshake” interface and the other as “Ni2+-mediated” (Figure 2). It is important to note that,
while the first interaction mode is accepted to be present in physiological conditions, the authors state
that “Ni2+-mediated” interaction is probably due to the purification conditions. However, considering
(1) the tendency of STAT3 to form paracrystals [23,55] or nuclear bodies to defend itself from
phosphorylation and (2) that its function is directly influenced by metals [56], also the “Ni2+-mediated”
interface could be necessary for some physiological, still not well characterized, effects.
Interestingly, in the previously discussed study [27], the NTD dimerization was also investigated
by SEC—small-angle X-ray scattering (SEC-SAXS) experiment. The obtained results confirmed not
only the NTD dimerization, but also that this methodology is a very useful tool to study dynamics and
aggregation prone samples.
Computational studies also have been carried out to investigate the structure of STAT3 monomer
and dimer. In 2012, Husby et al. [57] investigated the interaction between STAT3, USTAT3 and DNA by
molecular dynamics simulations obtaining interesting data about the importance of specific residues
in the interaction with DNA.
More recently, some of us used protein-protein docking and molecular dynamics simulations
to investigate the structure of USTAT3 dimers not bound to DNA [25]. In particular, the models
obtained by docking were screened by the available structural information and then molecular dynamics
simulations were used to relax the models. Finally, Molecular Mechanics-Generalized Born Surface Area
(MM-GBSA) [58] calculations have been used to identify the residues more important for the dimer stability.
Figure 2. (A) NTD handshake dimerization mode and (B) details about the interactions stabilizing this
configuration. The two NTDs are shown in blue and red cartoons and the residues important for the
dimerization in green sticks. (C) Ni2+ mediated multimerization (in this case the different NTDs are
depicted in green, violet, yellow and sandy and (D) details about the Ni2+ coordination. Structures
extracted from the PDB entry 4ZIA [27].
Int. J. Mol. Sci. 2018, 19, 1591 6 of 14
5. Drug Design
Over the years, experimental information about the structure of STAT3 and computer simulations
have been used to (1) identify new inhibitors, (2) to better understand the binding mode of existing
inhibitors and (3) to improve their affinity for the target. A list of papers published in the last five years,
together with a summary, is reported in Table 2. Multiple strategies, involving different protein regions,
have been followed aiming to design potent and selective inhibitors of the STAT3 functions [59–62].
The goal of this section is to give an overview about how structural biology influenced the
discovery of new biologically active molecules. The medicinal chemistry efforts to discover STAT3
inhibitors have been extensively reviewed elsewhere [9,11,63–66]. Here, therefore, we will discuss only
selected examples of ligand-based drug design and how computational, structural and biochemical
techniques have been used to understand the binding mode of STAT3 inhibitors. The majority of the
ligands have been designed to antagonize the phosphorylation induced protein dimerization. In this
case, the rationale that guided the screening and the structural optimization of the lead compounds
was the identification of molecules able to compete with p-Tyr705 for binding to a site located in the
SH2 domain [67].
Among the STAT3 inhibitors designed to compete for p-Tyr705 binding site a large group is
formed by phosphopeptides. This approach was firstly attempted by Turkson et al. in 2001 [68].
Starting from the sequence of the SH2 binding peptide (PY*LKTK, where Y* indicates p-Tyr705)
they carried out a systematic analysis of the binding properties of derived peptides. After an
in-depth characterization of the in vitro and in vivo activity of PY*LKTK and the other synthesized
peptides, they concluded that the sequence XY*L (X is a generic residue) represents the minimal active
sequence. Using a similar approach McMurray and coworkers [69] considered tyrosine-phosphorylated
hexapeptides, selected taking into consideration the STAT3 docking sites for gp130, LIFR, EGFR,
IL-10R, and GCSFR. They discovered one peptide (sequence Y*LPQTV) able to block STAT3
dimerization and DNA binding with an IC50 of 150 nM (determined by electrophoretic mobility
shift assay, EMSA) [69] or 290 nM (determined by fluorescence polarization, FP) [70]. The subsequent
optimization of this peptide benefitted of the structural information about the interaction between
one STAT3 monomer and the Y*LKTKF peptide from the other STAT3 molecule forming the
“canonical” dimer reported in the seminal work of Becker et al. [21] (PDB code 1BG1, Figure 3).
However, the X-ray structure did not give any information about the interaction of the PQTV portion
of the lead peptide, because this is not present in the co-crystallized peptide. Then, structure-activity
relationship (SAR) analyses were performed to identify residues that are important for binding
and could be modified. Collectively, these studies led to the identification of a peptidomimetic
(hydroxycinnamoyl-Tyr(PO3H2)-Leu-cis-3,4-methanoPro-Gln-NHBn) that showed an IC50 of 150 nM
in FP assays [70]. More recently, the same group published a peptidomimetic inspired by their
best phosphopeptide that displayed an IC50 162 nM [71]. Structure-based computational methods
have been applied to identify many small organic compounds able to modulate STAT3 activity by
binding to the SH2 domain. For example, the structural and computational analysis of the interaction
between phosphotyrosine peptides and STAT3 guided the development of a peptidomimetic molecule
(S3I-M2001) [72]. The list of the molecules discovered by virtual screening includes STAT-21 [73],
STX-0119 [74] and a group of three molecules named cpd3, cpd30, and cpd188 that compete with Y*
for its binding site in the SH2 domain [75].
Computational methods, based on the use of the available structural information, have also been
used to improve our knowledge of how already identified compounds interact with STAT3. For example,
Brambilla et al. [76] used an integrated approach between computational and experimental methods to
identify the binding site for OPB-31121, a STAT3 inhibitor discovered by biochemical/cellular assays.
In particular, computational studies based on docking, molecular dynamics and free energy calculations
suggested that OPB-31121 binds to a site different from that of other characterized STAT3 inhibitors, such
as S3I.201. Free energy calculations gave essential suggestions about the residues more critical for the
binding of OPB-31121 to the SH2 domain. Then, two mutants (S636A and V637A) were expressed and their
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ability to bind OPB-31121 and S3I.201 was tested by isothermal titration calorimetry (ITC) experiments.
Interestingly, these mutations abrogated only the binding of OPB-31121 and not of S3I.201, confirming that
computer simulations correctly identified the specific OPB-31121 binding site. This strategy was used by
the same group to investigate the binding of another structurally similar STAT3 inhibitor, OPB-51602 [5].
Importantly, also other STAT3 domains have been explored to design innovative inhibitors.
The relevance of the NTD in USTAT3 dimerization, oligomerization [66] and other cellular processes
motivated Timofeeva at al. [40] to design peptides able to bind this region and inhibit specific STAT3
functions. Starting from the analysis of the STAT4 NTD dimers structure, available at the time of their
study (PDB code 1BGF [54]), they selected two helices of 12 and 20 residues involved in the binding
surface. Then, they synthetized peptides considering the sequence the corresponding to the same
protein region in STAT3 and hypothesizing that they might antagonize the NTD dimer formation.
The complex between the two peptides and the STAT4 NTD was investigated by nuclear magnetic
resonance (NMR). The structure with the 20-residues long peptide was not determined because it
induced protein aggregation, probably due to NTD unfolding. Also, the experiments on the 12-residues
long peptide, analog of helix 2 (Figure 4), suggested an effect on the NTD structure. Nevertheless, in this
case, it was possible to carry on the analysis and observe that the majority of the chemical shift changes
were located in the region occupied by helix 8. The authors concluded that a new interaction interface,
not detected in the NDT STAT4 structure [54], was induced by the presence of the 12-residues peptide.
Finally, starting from the helix 2 analog, a library of mutant peptides was synthetized and their
ability to suppress STAT3 signaling in cancer cells was evaluated. To note, these peptides were fused
with penetratin, a peptide able to permit the entrance in the cells of non-cell penetrating molecules [77].
Some of the synthetized peptides demonstrated STAT3 inhibitory activity in the gamma
activation sequence (GAS)-luciferase reporter assays and inhibition of proliferation of Michigan
Cancer Foundation (MCF)-7 breast cancer cells, confirming that the NTD domain is a protein region
suitable for the development of new anticancer drugs.
In summary, these studies provide clear evidence of the crucial role of structural biology
information for the identification and optimization of STAT3 inhibitors and indicate that future
studies cannot disregard the use of computational and experimental structural techniques.
Figure 3. Insight on the Y*LKTKF (represented in sticks, carbon atoms colored in magenta) interaction
in a STAT3 dimer (represented as green cartoons, PDB code 1BG1 [21]). Important residues in contact
with Y* are depicted as spheres (carbon atoms colored in orange).
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Figure 4. STAT4-NTD domain (PDB code 1BGF [54]), alpha-helixes are color coded 1-red, 2-blue,
3-yellow, 4-bluewhite, 5-cyan, 6-magenta, 7 orange, 8 gray.
Table 2. Summary of more relevant papers, published in the last five years, in which structural
biology and computational methods were used to design and/or to better understand the molecular
determinants of STAT3 inhibitors.
Title Structural Experimental and/or Computational StructuralBiology Contribution Year Reference
Arctigenin Inhibits STAT3 and exhibits anticancer potential in
human triple-negative breast cancer therapy.
Use of docking and molecular dynamics simulations to understand the
binding mode of Arctigenin (a STAT3 inhibitor). 2017 [78]
Mitochondrial dysfunction induced by a SH2 domain-targeting
STAT3 inhibitor leads to metabolic synthetic lethality in
cancer cells
Use of docking and molecular dynamics simulations to characterize the
binding mode of OPB-51602, a small molecule currently in clinical trials,
to STAT3.
2017 [5]
Discovery of an Orally Selective Inhibitor of Signal Transducer
and Activator of Transcription 3 Using Advanced Multiple
Ligand Simultaneous Docking
Use of Advanced Multiple Ligand Simultaneous Docking (AMLSD) to
design compounds able to directly inhibit both phosphorylation and
dimerization of STAT3 protein.
2017 [79]
Identification of New Shikonin Derivatives as STAT3 Inhibitors Discovery of to discover PMMB-187, a new STAT3 inhibitor bymodification of shikonin scaffold guided by computational modeling. 2017 [80]
Identification of New Shikonin Derivatives as Antitumor Agents
Targeting STAT3 SH2 Domain.
Discovery of PMM-172, a new STAT3 inhibitor, via molecular docking
and scaffold modification of shikonin. 2017 [81]
MMPP Attenuates Non-Small Cell Lung Cancer Growth by
Inhibiting the STAT3 DNA-Binding Activity via Direct Binding
to the STAT3 DNA-Binding Domain
Use of molecular docking for the rational design of 16BHPB,
a STAT3 inhibitor. 2017 [82]
Identification of novel small molecules that inhibit
STAT3-dependent transcription and function
Use of docking studies to understand the binding mode of new STAT3
inhibitors identified by high-throughput screening. 2017 [83]
Small molecules inhibit STAT3 activation, autophagy, and cancer
cell anchorage-independent growth Molecular docking of STAT3 inhibitors to predict their binding mode. 2017 [84]
Discovery of monocarbonyl curcumin-BTP hybrids as STAT3
inhibitors for drug-sensitive and drug-resistant breast
cancer therapy
Docking studies to predict the binding mode of new STAT3 inhibitors. 2017 [85]
Applying Small Molecule Signal Transducer and Activator of
Trancription-3 (STAT3) Protein Inhibitors as Pancreatic
Cancer Therapeutics
Docking of STAT3 inhibitors and visualization of the computed
receptor-ligand complexes. 2016 [86]
4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small
molecule inhibitors of STAT3 signaling pathway Docking studies of a new STAT3 inhibitor to confirm its binding mode. 2016 [87]
Design, synthesis and evaluation of XZH-5 analogues as STAT3
inhibitors
Structure activity relationship (SAR) to design new STAT3 inhibitors
using docking studies to predict their binding mode. 2016 [88]
Design, synthesis and biological evaluation of benzyloxyphenyl-
methylaminophenol derivatives as STAT3 signaling
pathway inhibitors
SAR studies of benzyloxyphenyl-methylaminophenol scaffold and
docking studies to confirm inhibitors binding mode 2016 [89]
A novel small molecule STAT3 inhibitor, LY5, inhibits cell
viability, colony formation, and migration of colon and liver
cancer cells
Evaluation of LY5 inhibition and docking studies to understand its
binding mode 2016 [90]
Screening and biological evaluation of a novel STAT3 signaling
pathway inhibitor against cancer
Identification of new STAT3 inhibitors (directed to SH2 domain) by
docking studies using SPECS libraries (202,490 compounds). 2016 [91]
Selective Inhibition of STAT3 with Respect to STAT1: Insights
from Molecular Dynamics and Ensemble Docking Simulations
Molecular mechanisms studies about the selectivity of 13
experimentally tested STAT3 inhibitors by molecular dynamics and
ensemble docking simulations.
2016 [92]
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Table 2. Cont.
Title Structural Experimental and/or Computational StructuralBiology Contribution Year Reference
Antagonizing STAT3 activation with benzo[b]thiophene 1,
1-dioxide based small molecules
Discovery of new STAT3 inhibitors via structure-based drug design
methods, using benzo[b]thiophene 1, 1-dioxide (BTP) as
lead compound.
2016 [93]
Alantolactone selectively suppresses STAT3 activation and
exhibits potent anticancer activity in MDA-MB-231 cells
Structure-based molecular docking study used to investigate the
binding mode of alantolactone, found to be a STAT3 inhibitor, and
STAT3
2015 [94]
Identification of Lead Compounds as Inhibitors of STAT3: Design,
Synthesis and Bioactivity Virtual screening to find new STAT3 inhibitors. 2015 [95]
Eriocalyxin B Inhibits STAT3 Signaling by Covalently Targeting
STAT3 and Blocking Phosphorylation and Activation of STAT3
Computational modeling analysis of the mechanism of action EB,
a natural compound able to act as a STAT3 inhibitor. 2015 [96]
Hitting the right spot: Mechanism of action of OPB-31121, a
novel and potent inhibitor of the Signal Transducer and Activator
of Transcription 3 (STAT3)
In silico studies to understand the binding mode of a previously known
STAT3 inhibitor. 2015 [76]
Identification of STAT1 and STAT3 Specific Inhibitors Using
Comparative Virtual Screening and Docking Validation Virtual screening to find new STAT3 inhibitors. 2015 [97]
Discovery of a small-molecule inhibitor of STAT3 by ligand-based
pharmacophore screening Pharmacophore based virtual screening. 2014 [98]
A novel inhibitor of STAT3 homodimerization selectively
suppresses STAT3 activity and malignant transformation
Structure activity relationship (SAR) studies using a previously
published S3I-201 compound as a lead and docking studies to
understand the binding mode of the new inhibitors
2013 [99]
Binding Modes of Peptidomimetics Designed to Inhibit STAT3
Molecular docking combined with molecular dynamic simulations to
model to model the structures of 12 peptidomimetic inhibitors bound
to the SH2 domain of STAT3.
2012 [100]
6. Conclusions
In summary, despite difficulties in the expression and crystallization of the protein, structural
biology investigations have been of great help in improving our understanding of the STAT3 structure
and its functional mechanism.
The structures available in the PDB have been the starting point for a large number of studies in
which computer simulations have been used to identify new drugs, improving their affinity for the
target or simply to understand their biding mode.
However, a lot of issues, in particular concerning the structure of USTAT3 dimers, the interaction
with specific drugs but also the role of NTD domains in the phosphorylated dimers and other molecular
events, are still open and should be the subjects of new studies.
Hopefully, in the next future the integration between computational, structural and biophysical
techniques will help to better characterize from the structural point of view the drug protein complexes
and those STAT3 species that have eluded the attempts of characterization carried out so far.
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Abbreviations
NTD N-terminal domain
STAT3 Signal transducer and activator of transcription 3
USTAT3 Unphosphorylated STAT3
TAD Trans activation domain
LD Linker domain
DBD DNA binding domain
CDD Coiled coil domain
NTD N-terminal domain
SH2 SH2 domain
p-Tyr705 Phosphorylated tyrosine 705
PTMs Post-transcriptional modifications
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